Walgreens and Breakthrough T1D Forge $16M Retail Healthcare Alliance

NEW YORK, NY – November 12, 2026 — The shifting landscape of healthcare distribution has increasingly positioned the retail pharmacy not just as a dispensary, but as the vanguard of chronic disease management. This structural evolution took a significant leap forward today with the announcement of a multifaceted national partnership between Breakthrough T1D—the leading global type 1 diabetes research and advocacy organization—and the Walgreens Foundation.

Through a combined philanthropic model that includes a $1 million direct cash commitment over three years from the foundation and a projected $15 million point-of-sale checkout campaign launching in May 2027, the alliance bridges the gap between specialized biomedical research and broad retail healthcare. But beyond the financial injection, the partnership signals a strategic operational pivot: transforming the neighborhood pharmacist into a primary navigator for early disease detection and clinical trial recruitment.

"Breakthrough T1D is excited to welcome the Walgreens Foundation as a national partner, and we are deeply grateful for their generous commitment to the type 1 diabetes community," said Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D. "Walgreens is already a steady and trusted local presence in communities, helping this partnership meet people where they already receive care. With a shared focus on improving lives and building a healthier tomorrow, partners like the Walgreens Foundation are essential to making everyday life with type 1 diabetes better today while we work toward cures."

The Retail Frontline: Transforming Pharmacy Staff into Type 1 Diabetes Navigators

For decades, the bottleneck in type 1 diabetes (T1D) care has been the reliance on specialized endocrinology clinics for both early detection and advanced disease management. By integrating ACPE-accredited continuing education activities specifically designed for the pharmacy chain's network of nearly 90,000 healthcare service providers, this partnership effectively decentralizes clinical awareness.

Pharmacists are increasingly recognized as critical touchpoints in chronic disease management. With public health advocates pushing for expanded clinical scopes, empowering community pharmacists with advanced training on T1D management, continuous glucose monitors (CGMs), and early biomarker screening represents a massive scaling of frontline care. The newly accredited curriculum will equip these professionals to better support the over 1.5 million Americans currently living with the autoimmune condition.

More importantly, this educational rollout aligns with the American Diabetes Association’s latest Standards of Care, which strongly recommend autoantibody-based screening for early-stage T1D in at-risk individuals. Currently, screening for predictive markers like GADA, IA-2A, and ZnT8A is largely confined to research settings or delayed by complex clinical workflows and billing hurdles. By educating community healthcare providers on the importance of these screenings, the initiative lays the groundwork for a future where early detection is initiated in the same aisles where patients pick up their monthly prescriptions.

The psychological burden of chronic illness management is another critical vector addressed by this expanded clinical scope. The advocacy organization has recently pioneered initiatives to equip professionals with the tools to manage high rates of diabetes distress, anxiety, and depression. Integrating these holistic care principles into the retail setting ensures that patients receive not just logistical support for medical devices, but empathetic guidance through the daily grind of autoimmune management.

Micro-Donations, Macro Research: Evaluating the Retail Philanthropy Model

At the heart of the financial strategy is an ambitious goal to raise $15 million over three years through checkout fundraising campaigns across approximately 8,500 stores in the U.S. and Puerto Rico. While micro-donations might seem incremental, the macroeconomic power of retail philanthropy is staggering.

According to recent industry benchmarks evaluating charity checkout champions, point-of-sale fundraising campaigns collectively raised over $275 million nationwide in a single year, with the average donation hovering around $1.13 per interaction. With the retail giant serving nearly 9 million customers daily, the sheer volume of foot traffic makes the $5 million annual target highly realistic. Industry analysts note that automated pin-pad asks and computerized front-of-store integrations have turned the checkout aisle into one of the most reliable funding pipelines for biomedical research.

Consumer sentiment data further validates this approach. Market research indicates that over 70 percent of consumers have participated in checkout charity campaigns, with a majority actively appreciating the opportunity to contribute to cause-specific, time-bound initiatives. Set-dollar prompts have proven highly effective, requiring minimal cognitive effort from the shopper while generating massive aggregate capital.

These funds are not merely for awareness; they are critical capital for aggressive investments in disease-modifying therapies and cell therapy research. Over the past decade, hundreds of millions have been directed into therapies aimed at slowing or halting the immune attack on beta cells. This includes funding the research behind Tzield (teplizumab), an FDA-approved immunotherapy capable of delaying the onset of stage 3 T1D by an average of two years. Furthermore, checkout donations will indirectly support the broader ecosystem of cell therapy, such as the backing of lab-grown islets now utilized in advanced stem cell clinical trials, and venture investments in early-stage biopharma companies.

Beyond Childhood: Dismantling the Adult Type 1 Diabetes Myth at Scale

Perhaps the most culturally significant aspect of this partnership is the platform it provides to correct a pervasive and dangerous medical misconception: that type 1 diabetes is strictly a pediatric disease. This outdated narrative is the primary reason the global research organization officially rebranded from the Juvenile Diabetes Research Foundation earlier this year.

The epidemiological reality is stark. Diagnosis in adulthood accounts for nearly 50 percent of all new T1D cases. Because the onset of the condition has nothing to do with diet or lifestyle—stemming instead from a complex interplay of genetic factors and environmental triggers—adults presenting with symptoms are frequently misdiagnosed with type 2 diabetes. This misdiagnosis delays crucial insulin therapy and increases the risk of life-threatening diabetic ketoacidosis, alongside long-term complications affecting the kidneys, eyes, and heart.

"Walgreens has served as a cornerstone in neighborhoods across the country for more than a century, helping people lead healthier lives through personal care, trusted advice, and accessible services," said Abbe Luersman, Walgreens Executive Vice President, Chief Human Resources Officer, and President of the Walgreens Foundation. "With more than 1.5 million Americans living with type 1 diabetes today and incidence rates rising, the Walgreens Foundation has a tremendous opportunity to support the community and help people truly see T1D through this partnership."

The sheer scale of the crisis demands this level of corporate-nonprofit synergy. Globally, the autoimmune condition impacts 9.5 million people, and incidence rates are climbing. Up to 90 percent of new cases have no familial connection, meaning predictive screening cannot be limited strictly to those with a known family history.

Leveraging a massive physical footprint to disseminate accurate public health information serves as a powerful corrective measure. By normalizing the conversation around adult-onset T1D at the pharmacy counter, the partnership aims to dismantle the childhood myth at scale. When an adult patient expresses concerns about sudden weight loss and fatigue, a pharmacist trained through this newly accredited curriculum is now better positioned to suggest autoantibody screening rather than defaulting to type 2 assumptions, representing the precise structural shift required to modernize autoimmune care in the 21st century.